|
Topotecan more drug_interactions |
|
Inputs from various sources such as WHO bulletins, Internet, Indian Army recee reports etc. indicated the presence of communicable diseases MT Malaria, Lassa fever, HIV ; and infestation of typical snakes spitting cobra ; and peculiar insects Tumbu Fly, Acid Fly ; Moreover, health education was necessary.
Fig. 57. Mollusc. Gill of a 5 old rainbow trout Oncorhynchus mykiss showing a single glochidium larval freshwater mussel Margaritifera margaritifera ; and numerous eggs of the blood fluke Sanguinicola sp. with developing embryos arrows ; . Shell valves of the glochidium are clamped onto gill lamellar tissue, and the presence of the parasite has induced fusion of the tips of the lamellae. H&E. Scale bar 100 m.
Topotecan in Cervical and Uterine Carcinoma second-line therapy was free of disease at 30 months of follow-up. The most common adverse events were anemia and neutropenic fever, which were experienced by six and four patients, respectively. Fifty-three percent of patients required G-CSF and or recombinant erythropoietin support. Results of this early trial suggest that topotecan is active in uterine papillary serous carcinoma. Currently, the role of topotecan in treating endometrial carcinomas has not been established. However, the promising results of these early trials have led to additional trials designed to further elucidate the role of topotecan. The Florida Society of Gynecologic Oncologists continues to enroll patients with advanced, persistent, or recurrent endometrial cancers into a dose-escalating phase I II trial investigating weekly topotecan [58]. Topotecan doses up to 4.5 mg m2 week have been well tolerated. However, caution should be used when administering topotecan in previously irradiated patients because of potential irreversible bone marrow suppression associated with radiotherapy. Updated results from this trial and results from other trials will begin to characterize the role of topotecan in the treatment of endometrial carcinomas. SUMMARY Improvements in the early detection of cervical and uterine cancers have substantially reduced the associated mortality rates over the past decades. However, the mortality rates in patients diagnosed with advanced cervical or uterine cancer have remained unchanged over the past 25 years. Treatment of early cervical and endometrial carcinomas with hysterectomy alone or with radiotherapy is associated with a high cure rate for these patients. However, patients with advanced stages of these diseases are rarely cured. Currently, patients with advanced cervical cancer are treated with radiotherapy and cisplatin; however, most cervical cancer patients will eventually relapse. Patients with advanced-stage endometrial carcinoma are often treated with a doxorubicin cisplatin combination regimen. However, the majority of these patients also experience recurrent disease. Thus, there is a need for improved treatment options for patients with these nonovarian gynecologic malignancies. Several new cytotoxic agents have been investigated in both diseases. Of these agents, topotecan is one of the most characterized. The unique mechanism of action of topotecan and the success of this agent in the treatment of patients with relapsed ovarian cancer make it an attractive treatment option for patients with advanced cervical and endometrial carcinomas. In early reports, topotecan has demonstrated promising antitumor activity in patients with advanced or recurrent cervical cancers. In addition, preliminary data also suggest that.
Topotecan more drug_interactions
Important transcriptional regulation is in controlling CAR expression. Therefore, we developed a quantitative RT-PCR assay for CAR. Interestingly, the effect of the agents on CAR mRNA was variable Fig. 2B ; , and significant increases were not seen P 0.05 ; . Furthermore, no clear correlation between CAR mRNA levels and transgene expression or CAR FACS could be detected. Effect of Combinations of Agents on Transgene Expression. Various combination treatments resulted in dramatic improvement in transgene expression in ovarian cancer cells Fig. 2C ; . For Hey cells, luciferase expression was increased 4.9-fold P 0.00028 ; with etoposide and topotecan, 19.4-fold P 0.0001 ; with etoposide and trichostatin A, and 15-fold P 0.0001 ; with topotecan and trichostatin A. The combination of topotecan and FR901228 was effective in all tested cell lines, increasing transgene expression 52-fold P 0.0043 ; , 4.3-fold P 0.014 ; , and 41-fold P 0.0077 ; on OV-4, SKOV3.ip1, and Hey cells, respectively. Furthermore, etoposide and FR901228 increased marker expression on OV-4 cells 7.8fold P 0.028 ; , whereas etoposide and topotecan and trichostatin A were effective on OV-4 1.9-fold increase; P 0.032 ; and Hey cells 17-fold increase; P 0.0001 ; . Effect of Agents on Adenoviral Entry into Cells. The previous experiments demonstrated the increase of cell surface CAR, as detected by FACS, which led to increases in transgene expression and subsequent protein production. Nevertheless, we sought to confirm that the increased CAR allowed increased virus entry into cells. Cells were incubated in the presence of the agents, and virus internalization was allowed to occur, followed by careful washing of the unbound virus. In all cases, the agents were found to mediate increased entry of the virus into the cells Fig. 4 ; . Transgene Expression in Unpassaged Primary Human Ovarian Cancer Samples. Established cell lines may differ from unpassaged primary tumors with regard to receptor expression 35 ; . Thus, clinical samples were analyzed Fig. 5 ; . FR901228 significantly increased transgene expression in all patient samples [4.7-fold P 0.0021 ; , 5.0-fold P 0.0085 ; , 2.3-fold P 0.003 ; , and 2.5-fold P 0.0046 ; ]. Topotecan increased transgene expression in two of four patient samples [2.5-fold P 0.025 ; and 1.5-fold P 0.013 ; ]. The combination of etoposide and FR901228 increased transgene expression in two of four patient samples [3.4-fold P 0.032 ; and.
Haematological adverse events were more common in the cisplatin plus topotecan group.
Taxotere NSCLC 100, 102 TBNA. See Transbronchial fine needle aspiration TBNA ; Team approach xi Thoracic imaging 57 Thoracic malignancies 18FDG-PET 934 3D conformal radiotherapy SCLC 126 3D-CT volume 130 TNM 57, 59 lung cancer 58 nodal staging 58 T1-3 N2MO SNCLC surgery 139 Topotecan LS-SCLC 109 Tracers PET 85 Tracheobronchial nodes 66 Transbronchial fine needle aspiration TBNA ; 8 NSCLC mediastinal metastases 70 videobronchoscopy 9 Treatment response 18FDG-PET 912 T4 squamous cell carcinoma CT 64 18FDG-PET 64 T1 tumours CT 61 T3 tumours vs. T4 tumours 62 T4 tumours CT vs. MRI 64 detection 62 vs. T3 tumours 62 Tumour hypoxia 18F-fluormisonidazole 96 Tumours average size of 2 defined 20 movement with respiration 1301 T1-weighted coronal MRI tumour at left apex 33 T2-weighted MRI 61 UFT. See Uracil-tegafur UFT ; Ultrasmall superparamagnetic ironoxide nanoparticles USPIO ; 69 Ultrasound 33 Untreated lung cancer natural history of 2 Upper lobe tumour CT scan 9 Upper paratracheal nodes defined 67 and toradol.
Topotecan forums
10. Hossain, M.A., G.H. Reyes, L.A. Long, P.K. Mukherjee, and M.A. Ghannoum. 2003. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J. Antimicrob. Chemother. 51: 1427-1429!
With a recent report 23 ; , we found that pretreatment with LMB for 30 min inhibited NF- B activation not only by cytokines such as TNF Fig. 1A, lanes 911 ; but also by the DNA-damaging agent topotecan lanes 35 ; . Addition of LMB directly to nuclear extracts did not affect NF- B DNA binding Fig. 1A, lanes 6 and 7 ; , indicating that this chemical agent did not directly block NF- B's ability to bind DNA. Consistent with EMSA, LMB also inhibited TNF -induced NF- B transcriptional activation Fig. 1C ; . Unlike the proteasome inhibitor CI-I Fig. 1B Lower, lane 2 ; , LMB prevented I B degradation but did not cause accumulation of the phosphorylated I B form in TNF -treated cells Fig. 1B Lower, lanes 68 ; . However, LMB failed to prevent I B degradation and NF- B activation in enucleated cells Fig. 2 A and B, lane 3 ; . In enucleated cells, CI-I was able to prevent NF- B activation by inhibiting I B degradation Fig. 2B Upper, lane 2 ; causing accumulation of both phosphorylated Fig. 2B Upper, lane 6 ; and multiubiquitinated I B forms Fig. 2B Lower, lane 6 ; . Consistent with the known action of LMB against CRM1 in the nucleus 12, 1416, 30 ; , these findings indicate that inhibition of NF- B activation by LMB indeed requires an intact nucleus and toremifene.
R., Fossella, F. V., Glisson, B. S., Lee, J. S., Murphy, M., Kemp, B. L., Lee, J. J., Kane, J., Robinson, R. A., Kurie, J. M., Huber, M. H., Raber, M. N., and Hong, trial of topotecan in patients with advanced non-small.
Dear New Pathways, ACT returned most of my money from a trip to Cork to have stem cells but conveniently failed to send the full amount. I was promised a refund of my travel expenses, but they have not given me this, which has resulted in me losing over 400 and torsemide
NDA 20-622 S-015 Page 28 COPAXONE does not contain preservatives. Therefore, it should be used right away after you reconstitute mix ; it. If you cannot use it right away after reconstitution, throw it away. Manufactured For: TEVA Neuroscience LLC Kansas City, MO 64134 Manufactured By: Ben Venue Laboratories Bedford, OH 44146 or TEVA Pharmaceutical Industries, Ltd. Kfar-Saba, 44102, Israel
If the mother is not married at the child's birth, she may choose any last name she wishes for the child on the Birth Certificate without the father agreeing. If a child has a father's last name and a Paternity fatherhood ; Acknowledgment form has not been signed by both parents, a legal father has not been determined. However, when both parents sign a Paternity fatherhood ; Acknowledgment form, they must agree how the child's name should appear on the Birth Certificate and tracleer.
Topotecan price
The cytotoxicity of topotecan is thought to be due to double strand dna damage produced during dna synthesis , when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase i, and dna.
Gurmeet Singh, Deputy Chief Wildlife Warden, Punjab, who studied the Bank Myna for his M . degree 1992. The ecology of the Bank Myna Acridotheres fuscus ; in an urban environment. University of Bombay: Bombay. ; , backs my inference. On returning to Chandigarh it was not the turn of the Jungle Myna to astonish me with such vast congregations on my chosen corner in the Rose Garden where the Common Myna stood driven to near anonymity; at least for about ten days any way. Perhaps it is best to reproduce the observations I noted: 1. 28th March, 07: 00 hours: Jungle Mynas are just about everywhere. On one Jacaranda tree alone, there are 54 and elsewhere in the Rose Garden I saw 5 Common Mynas only. 2. 30th March, 07: 30 hours: Jungle Mynas in flocks of 10 to 50. They are so crazy over the nectar of the Bottle Brush Callistemon lanceolatus flowers that you could throw a butterfly net over them, almost! 3. 1st April, 08: 15 hours: Jungle Mynas, no change. 4. 2nd April, 08: 00 hours: 33 Jungle Mynas on a Semal tree Salmalia malabarica and 20 on a nearby Silver Oak Grevillea robusta. In contrast only four Common Mynas encountered. 5. 4th April, 07: 30 hours: The Jungle Mynas are also attracted to the nectar of the Silver Oak flowers. 6. 7th April, 07: 30 hours: Jungle Mynas still around in large numbers but beginning to form smaller congregations of 5-15 birds. The rose garden full of myna chatter. 7. 10th April, 07: 30 hours: Jungle Mynas now more or less in the same numbers as Common Mynas. The return `passage' of the Jungle Mynas may well have begun. 8. 14th April, 08: 00 hours: Jungle Mynas diminishing in numbers. Blossoms on Bottle Brush and Silver Oaks have faded out. 9. 16th April, 07: 30 hours: One flock of 20 Jungle Mynas. 10. 21st April, 07: 00 hours: One reason why so few of the Common Mynas were visible is perhaps because the peak `passage' of the Jungle Myna here coincides with the peak nesting activity of the Common. There is no direct evidence of the Jungle Myna nesting here. Surely there must be a few Jungle Mynas resident here. Should they not be nesting? One pair was seen exploring a nest-cavity on a Semal tree and another contesting a cavity with a Rose-ringed Parakeet Psittacula krameri and trandolapril.
Doxil® : improved therapeutic profile and more cost effective than hycamptin® in ovarian cancer 11 21 2002 ; according to a recent article published in the annals of oncology , doxil® is more convenient and drastically reduces medical costs while maintaining effectiveness compared to hycamptin® topotecan ; for the treatment of recurrent ovarian cancer 1.
Two compounds, topotecan and PhIP Fig. 2, B and C ; , both male and female mice showed a significant difference between wild-type and Bcrp1 mice. Note that plasma levels of intravenously administered Bcrp1 substrates are generally higher in Bcrp1 mice because of decreased elimination Jonker et al., 2002; van Herwaarden et al., 2003 ; . Bcrp1-mediated pharmacokinetic sex differences thus affect a variety of substrates. Western Blot Analysis of the Expression of Mouse Bcrp1 and Human BCRP in Both Sexes. To assess whether the sex difference observed in the pharmacokinetics of Bcrp1 substrates was caused by a sex difference in Bcrp1 expression, we performed Western blot analysis of the primary organs determining plasma pharmacokinetics i.e., liver, small intestine, and kidney ; , in male and female mice Fig. 3 ; . We did not observe any clear sex-dependent difference in Bcrp1 expression in the small intestine and kidney Fig. 3A ; . However, there was a marked sex difference in the liver samples of adult mice from two different mouse strains FVB and 129 Ola ; , with expression consistently higher in the male mice Fig. 3B ; . A dilution series showed that the difference was on the order of 2- to 3-fold in FVB mice data not shown ; . We also assessed whether the sex difference in hepatic Bcrp1 levels was dependent on age. At 10 days after birth there was no sex difference Fig. 3C ; , whereas around 5 weeks puberty ; the sex difference was already similar to that in adults data not shown ; . Because the lack of difference in plasma levels of nitrofurantoin between wild-type and Bcrp1 female mice Table 1 ; was not in accordance with the 5-fold lower plasma and tranylcypromine.
Topotecan structure
Refers to the formulary in which the nurse trained. NPF refers to the Nurse Prescribers' Formulary or the District Nurse and Health Visitors Formulary ; . NPEF refers to Nurse Prescribers' Extended Formulary. - indicates those items which have been personally administered by the GP. For prescribing only GPs personally administered items are submitted separately and therefore can be separately identified from other prescriptions. For dispensing GPs such items are not separated out and personal administration is assumed by type of product eg injection and topotecan.
Results Selection of Resistant Lines and Analysis of Cross-Resistance. Cell lines nullizygous for Mdr1a, Mdr1b and Mrp1 were selected for resistance to topotecan, mitoxantrone or doxorubicin see "Materials and Methods" for details ; . The embryo fibroblast line MEF3.8 yielded the topotecan-resistant subline T6400 and the mitoxantrone-resistant subline M32. The ear fibroblast line KOT52 yielded a doxorubicinresistant subline, D320. Compared with their parental lines, the sublines were each more than 100-fold resistant to the selecting drug but remained sensitive to paclitaxel, vincristine and cisplatin Table 1 ; . The T6400, M32 and D320 lines were all highly cross-resistant to topotecan and mitoxantrone. The T6400 and M32 lines also showed some cross-resistance to anthracyclines and bisantrene a compound structurally related to mitoxantrone ; but at a much lower level than the doxorubicin-selected D320 line. The D320 line was also much more resistant to etoposide. Reduced Drug Accumulation and Increased Efflux. Doxorubicin and mitoxantrone interfere with topoisomerase II activity, whereas topotecan acts on a different target, topoisomerase I. Cross-resistance to both types of drugs could be explained most easily by reduced cellular drug accumulation, which can be readily measured for mitoxantrone by flow cytometry. Indeed, as a function of either time Fig. 1A ; or drug concentration Fig. 1B ; , mitoxantrone accumulation was greatly reduced in all three of the resistant sublines compared with the sensitive parental lines. The accumulation deficits could be largely reversed by performing the assays under conditions that deplete cellular ATP Fig. 1C ; , which indicates that they are mediated by an ATP-dependent mechanism. The accumulation deficits were similarly reversed in the presence of GF120918, a known P-gp inhibitor 19 ; also reported to inhibit human BCRP 20 ; . Confocal scanning microscopy revealed no qualitative differences in the subcellular localization of mitoxantrone in resistant versus sensitive cells data and treprostinil.
Human renal cell carcinoma. Urol Res 28: 383-390. Fleck C, Gockeritz S and Schubert J 1997 ; Tubular PAH transport capacity in human kidney tissue and in renal cell carcinoma: correlation with various clinical and morphological parameters of the tumor. Urol Res 25: 167-171. Fleck C, Hilger R, Jurkutat S, Karge E, Merkel U, Schimske A and Schubert J 2002 ; Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan Hycamtin ; and raltitrexed Tomudex ; by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma. Urol Res 30: 256-262. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, Enomoto A, Anzai N, Narikawa S, Huang XL, Niwa T and Endou H 2004 ; Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 308: 1021-1029. Hasegawa M, Kusuhara H, Endou H and Sugiyama Y 2003 ; Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J Pharmacol Exp Ther 305: 1087-1097. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H and Sugiyama Y 2002 ; Functional involvement of rat organic anion transporter 3 rOat3; Slc22a8 ; in the renal uptake of organic anions. J Pharmacol Exp Ther 300: 746-753. Hirano M, Maeda K, Shitara Y and Sugiyama Y 2004 ; Contribution of OATP2 OATP1B1 ; and OATP8 OATP1B3 ; to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311: 139-146. Hosoyamada M, Sekine T, Kanai Y and Endou H 1999 ; Molecular cloning and functional.
Topotecan iv
The recommended dose of topotecan is 0.75 mg m2 day administered as an intravenous infusion daily on days 1, 2 and 3. Cisplatin is administered as an intravenous infusion on day 1 at a dose of 50 mg m2 day and following the topotecan dose. This treatment schedule is repeated every 21 days for 6 courses or until progressive disease and triac.
Topotecan overdose
Longitudinal design, resolution 425, opioid equianalgesic dose, blood group experiment and parathyroid hormone and calcitonin. Autonomic nervous system cold hands, perineum tearing, functional food legislation and osteoporosis recipes or diverticulitis nuts.
Topotecan treatment
Topo5ecan, topotevan, topotecah, 6opotecan, topot4can, topofecan, topotecam, toppotecan, topotwcan, topohecan, topotecxn, topotcean, otpotecan, topotexan, hopotecan, tpotecan, topotfcan, top0tecan, topotecna, topootecan.
Topotecan site wikipedia.org
Topotecan more drug_interactions, topotecan forums, topotecan price, topotecan structure and topotecan iv. Topotecan overdose, topotecan treatment, topotecan site wikipedia.org and topotecan regime or topotecan once weekly.
|
|
|
